To that end, an analysis of co-expression of CSNK2A1 and AR mRNA levels in PCa patient samples from The Cancer Genome Atlas (TCGA) was performed (Pan-Cancer Atlas; n = 494 samples). This evidence concerns the gene CSNK2A1 and posterior cortical atrophy.